WilmerHale Advises Tetraphase Pharmaceuticals in Agreement to be Acquired by Melinta Therapeutics

WilmerHale Advises Tetraphase Pharmaceuticals in Agreement to be Acquired by Melinta Therapeutics

Client News

Related Solutions

Lawyers with deep and broad experience counseling clients in every industry on the design, implementation, and interpretation of executive compensation arrangements and on general compensation and benefits issues.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions.
A deep and diverse practice focused on maximizing tax efficiencies and minimizing tax risks for clients nationally and internationally.

On June 4, 2020, Tetraphase Pharmaceuticals, Inc. (Nasdaq: TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA to treat serious and life-threatening infections, and Melinta Therapeutics, wholly owned by Deerfield Management, a healthcare investment management firm, announced that they have entered into a definitive merger agreement pursuant to which Melinta would acquire Tetraphase for an aggregate of $39.0 million in cash, plus an additional $16.0 million in cash potentially payable under contingent value rights to be issued in the proposed acquisition. Also on June 4, 2020, Tetraphase terminated its previously announced merger agreement with AcelRx Pharmaceuticals in order to enter into the definitive merger agreement with Melinta. The transaction is expected to close in the third quarter of 2020. 

WilmerHale is representing Tetraphase in the transaction, with a team led by Partners Stuart Falber, Hal Leibowitz and Chris Barnstable-Brown, which also included Counsel Doug Edwards and Associates Meghan Fay, Victoria Peluso and Gerard Fischetti on corporate and M&A matters, and Partners Kim Wethly, Julie Hogan Rodgers, Scott Kilgore and Associate Ben Kelsey on tax, executive compensation and employment and benefits matters.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel